Cite
Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine
MLA
Block, Stan L., et al. “Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine.” The Pediatric Infectious Disease Journal, vol. 29, no. 2, Feb. 2010, pp. 95–101. EBSCOhost, https://doi.org/10.1097/INF.0b013e3181b77906.
APA
Block, S. L., Brown, D. R., Chatterjee, A., Gold, M. A., Sings, H. L., Meibohm, A., Dana, A., Haupt, R. M., Barr, E., Tamms, G. M., Zhou, H., & Reisinger, K. S. (2010). Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine. The Pediatric Infectious Disease Journal, 29(2), 95–101. https://doi.org/10.1097/INF.0b013e3181b77906
Chicago
Block, Stan L., Darron R. Brown, Archana Chatterjee, Michael A. Gold, Heather L. Sings, Anne Meibohm, Adrian Dana, et al. 2010. “Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine.” The Pediatric Infectious Disease Journal 29 (2): 95–101. doi:10.1097/INF.0b013e3181b77906.